Public trial registry of the CCC-Munich

Trial ABBV-399

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
ABBV-399
World
Full title
:

Phase 2, offene Sicherheits- und Wirksamkeitsstudie von Telisotuzumab Vedotin (ABBV-399) bei Patienten mit vorbehandeltem c-Met+ nicht-kleinzelligem Lungenkrebs

World
EudraCT number
:
World
NCT number
:
World
Responsible organization
:
Asklepios Klinik Gauting, Telefon:
Indications
Classification Code Description
ICD-10-GM C34.- Bösartige Neubildung der Bronchien und der Lunge
- lung cancers
Trial design
World
Trial type
:
Interventional
World
Blinding type
:
Open
World
Phase
:
II
Status
World
Status
:
Recruitment active
Votes
World
Institutional review board - vote
:
Unknown
Initiiation & lock
World
Date of lock (planned / actual)
:
2025-01-16 / Unknown
Participants
Function Prename Surname Organization
World Principal Investigator NIELS REINMUTH Keine Organisationseinheit angegeben Magnifier